Prothena Corporation plc
PRTA
Market Cap$346.38M
Close$
$35.32
448.9% upside
Current Fair Value
448.9% upsideUndervalued by 448.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $346.38 Million |
|---|---|
| Enterprise Value | $-53,457,255.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.27 |
| Beta | -0.08 |
| Outstanding Shares | 53,827,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.14 |
|---|---|
| PEG | 18.84 |
| Price to Sales | 3.22 |
| Price to Book Ratio | 0.8 |
| Enterprise Value to Revenue | -0.39 |
| Enterprise Value to EBIT | 0.39 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.34 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Prothena Corporation plc
7 employees
CEO: Gene Kinney Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...